Wellbutrin SR Patent Case Will Be Early Application Of Festo Ruling
Executive Summary
GlaxoSmithKline's defense of its Wellbutrin SR (bupropion sustained release) patents will be an early real world application of the Supreme Court's decision in the Festo case